Posts tagged “GSK”
Veteran journalist Jim Shamp sees upside and downside in the recently announced job cuts at GlaxoSmithKline. After all, he notes, cuts in the past as GSK evolved locally from Burrough Wellcome to Glaxo to Glaxo Wellcome and today have produced a harvest of new companies, new ideas, and products. "Yes, a shakeup like GSK's cutback announcement is shattering," he writes. "But these are smart, talented people who will get back on their feet and contribute greatly to North Carolina's life science future."
RTP-based BioCryst Pharmaceuticals is launching a clinical trial of a potential treatment for Ebola with funding support from the U.S. government. Durham-based Chimerix and GSK also are involved in the Ebola battle.
Even as backers pledged $390 million for Ebola vaccines, Swiss researchers have suspended the testing of one of the leading Ebola vaccine candidates after some volunteers reported unexpected side effects. It's not the vaccine being tested by GlaxoSmithKline.
Several North Carolina firms are at the forefront of developing new treatments for the Ebola virus, but they face challenges in testing and delivering them, executives from Chimerix, Quintiles and GlaxoSmithKline say at a conference in RTP.
Dr. Derek Lowe, a veteran pharmaceutical scientist and long-time Internet blogger, was among the first to report details of GSK's 20% job force reduction in RTP. Fed information from friends and contacts within the industry, he has written several insightful blogs about what's happening at the drug giant and across the pharmaceutical industry, particularly in R&D. And he tells WRAL TechWire that GSK's cuts are a "severe blow" to the Triangle.
GlaxoSmithKline will lay off hundreds of research and development workers at its Research Triangle Park campus, the company said in an official notice to the state.
Up to 450 employees of drug giant GlaxoSmithKline who face being laid off may find employment quickly at Parexel, a life science research firm with an office in RTP. GSK says it has signed a letter of intent to create a GSK-focused group within Parexel.
Trending in the Triangle: Get the pulse of technology in the Triangle with the best in local technology, venture, biotech, and life science news on Wednesday, Dec. 3, 2014 as curated by @WRALTechWire.
In a statement, GlaxoSmithKline explains the cutbacks being made in research and development at Research Triangle Park and other locations. "Our proposed changes to R&D will sharpen the focus in discovery and development and reduce funding in certain areas of the pipeline," the drug giant says.
GlaxoSmithKline is preparing to lay off hundreds of workers in the U.S., according to various media reports. A company spokesperson in RTP, where the company operates its North American headquarters, confirms that a reorganization is underway but won't comment on specifics.
The Ebola outbreak isn't generating big headlines in the U.S. these days, but forthcoming layoffs at GlaxoSmithKline are a hot topic. Unfortunately for GSK, the job cuts have overshadowed the company's progress in developing the first vaccine for the deadly Ebola.
A new survey from the Human Rights Campaign finds that a record number of companies, including seven in North Carolina, received perfect scores in corporate inclusion for lesbian, gay, bisexual and transgender employees. Bank of America, Blue Cross Blue Shield of NC and GlaxoSmithKline are among those receiving a "100" on the Corporate Equality Index.
Uber regulation coming in NC?; IBM's $1.25B outsourcing deal; GSK Ebola vaccine update; FTC says TRUSTe deceived consumers; SAP to pay Oracle $359M
In today's Bulldog wrapup of tech and life science news: A N.C. General Assembly committee is to discuss possible Uber regulations; IBM lands a $1.25 billion outsourcing deal with Lufthansa; GSK's Ebola vaccine is safe in early tests; the FTC settles complaint with TRUSTe; and SAP will pay Oracle $359 million to settle a long legal battle.
The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March. And GSK is ramping up vaccine trial. Paul Allen chips in $100 million. But will all this be enough to stop Ebola?
Having been fined nearly $500 million in China for bribery, facing investigations in other countries and battling lagging revenue, GSK now faces more cost cuts and is contemplating a stock offering for its ViiV Healthcare. But GSK's CEO Andrew Witty defended himself and his strategy in discussing the drug giant's most recent quarterly earnings report on Wednesday. "Look at what we're able to achieve," he says.